Innovent Biologics signs $10.5bn oncology collaboration with Pfizer
— M&A
Innovent Biologics secures a $650m upfront cash payment from Pfizer, providing immediate balance-sheet firepower to advance its oncology pipeline without dilutive equity issuance.